Kedrion

Kedrion is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as hemophilia and immune system deficiencies. Kedrion was established in Italy in 2001, but the roots of the companies from which it was born stretch back several decades in the production of blood and plasma derived products.  A primarily family-owned business, it places a high value not only on the welfare of those who benefit from its products but also on the people and communities where it operates. Kedrion Biopharma develops and produces plasma-derived therapies, making them available to meet patients’ needs the world over. Kedrion Biopharma has a long history of collaboration with the Italian National Health System, and partners the country in its move toward self-sufficiency in plasma-derived products. They bring this experience and the dedication to that goal to potential partners around the world. In recent years Kedrion has expanded its operations – not only into the United States through Kedrion Biopharma Inc., but into Germany and Hungary as well. It now has a market presence in about 100 countries. In addition, it has acquired collection and production capacity as well as the rights to significant products for treating hemophilia and preventing Rh sensitization, a condition which can lead to Hemolytic Disease of the Fetus and the Newborn (HDFN). Kedrion looks forward to continued expansion and the wider sharing of its experience, know-how and technology to foster self-sufficiency of plasma-derived products in healthcare systems and communities around the world and to bring healthier and less restricted lives to people suffering from rare disorders. MISSION Kedrion produces and distributes human plasma-derived medicinal products used to treat and prevent rare and debilitating diseases and disorders.  Kedrion works to maintain excellent industry standards and aspires to ongoing improvement, in order to retain a leading position in Italy and to increase its share of the international market. It works to strengthen its role as the accredited partner of the medical, scientific and institutional communities.  Kedrion’s ambition is to enhance its worldwide role as a strategic partner of the national health systems of those countries which aim to become self-sufficient in the availability of plasma-derived products, also via technology transfer. Kedrion produces wealth for investors, employees and for the local community, consistently with its own vision and values: responsibility, transparency, confidence in and respect for people.